In contrast, since CD276 is a more specific marker for alloreacting memory CD4+ T cells—and alloreactive T cells in CD45RA-depleted grafts are preferentially recruited from the CD4+ compartment [2]—in vivo depletion of CD276+ T cells may lower the risk of infection and disease relapse by preferentially depleting alloreacting CD4+ T cells while sparing virus-specific and cancer cell-specific T cells. This evidence concerns the gene CD276 and cancer.